Cargando…

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Dongxu, Li, Yongwei, Liu, Xinwei, Yan, Sha, Guo, Xiaolan, Xu, Xiaona, Guo, Xiaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355074/
https://www.ncbi.nlm.nih.gov/pubmed/28103581
http://dx.doi.org/10.18632/oncotarget.14712
_version_ 1782515458170159104
author Pei, Dongxu
Li, Yongwei
Liu, Xinwei
Yan, Sha
Guo, Xiaolan
Xu, Xiaona
Guo, Xiaoxia
author_facet Pei, Dongxu
Li, Yongwei
Liu, Xinwei
Yan, Sha
Guo, Xiaolan
Xu, Xiaona
Guo, Xiaoxia
author_sort Pei, Dongxu
collection PubMed
description Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. Results manifested that humoral fibulin-3 sustained a pooled sensitivity of 0.62 (95% CI: 0.45–0.77) and specificity of 0.82 (95% CI: 0.73–0.89) in discriminating MPM patients from cancer-free individuals, corresponding to an AUC (area under the curve) of 0.81. For the survival analysis, fibulin-3 expression was not markedly associated with overall survival (OS) time of the MPM patients [HR (hazard ratio): 1.84, 95% CI: 0.75–4.56, P = 0.185]. In the subgroup analyses stratified by test matrix and ethnicity, data revealed that serum-based fibulin-3 examination achieved superior accuracy than plasma-based analysis (sensitivity: 0.77 versus 0.54; specificity: 0.85 versus 0.77; AUC: 0.92 versus 0.69); additionally, testing of fibulin-3 in Europeans retained higher efficacy than those in Americans and Australians. Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification.
format Online
Article
Text
id pubmed-5355074
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53550742017-04-15 Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis Pei, Dongxu Li, Yongwei Liu, Xinwei Yan, Sha Guo, Xiaolan Xu, Xiaona Guo, Xiaoxia Oncotarget Research Paper Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. Results manifested that humoral fibulin-3 sustained a pooled sensitivity of 0.62 (95% CI: 0.45–0.77) and specificity of 0.82 (95% CI: 0.73–0.89) in discriminating MPM patients from cancer-free individuals, corresponding to an AUC (area under the curve) of 0.81. For the survival analysis, fibulin-3 expression was not markedly associated with overall survival (OS) time of the MPM patients [HR (hazard ratio): 1.84, 95% CI: 0.75–4.56, P = 0.185]. In the subgroup analyses stratified by test matrix and ethnicity, data revealed that serum-based fibulin-3 examination achieved superior accuracy than plasma-based analysis (sensitivity: 0.77 versus 0.54; specificity: 0.85 versus 0.77; AUC: 0.92 versus 0.69); additionally, testing of fibulin-3 in Europeans retained higher efficacy than those in Americans and Australians. Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification. Impact Journals LLC 2017-01-18 /pmc/articles/PMC5355074/ /pubmed/28103581 http://dx.doi.org/10.18632/oncotarget.14712 Text en Copyright: © 2017 Pei et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Pei, Dongxu
Li, Yongwei
Liu, Xinwei
Yan, Sha
Guo, Xiaolan
Xu, Xiaona
Guo, Xiaoxia
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title_full Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title_fullStr Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title_full_unstemmed Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title_short Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis
title_sort diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355074/
https://www.ncbi.nlm.nih.gov/pubmed/28103581
http://dx.doi.org/10.18632/oncotarget.14712
work_keys_str_mv AT peidongxu diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT liyongwei diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT liuxinwei diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT yansha diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT guoxiaolan diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT xuxiaona diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis
AT guoxiaoxia diagnosticandprognosticutilitiesofhumoralfibulin3inmalignantpleuralmesotheliomaevidencefromametaanalysis